Skip to main content

Table 3 Outcomes and toxicity

From: Clinical outcomes and toxicity using Stereotactic Body Radiotherapy (SBRT) for advanced cholangiocarcinoma

Patient

Site treated

Follow-up (months)

RECIST score

Clinical Outcome

FFDM (months)

Site of progression

Acute toxicity

Grade

Late toxicity

Grade

1

Liver

25.5

PR

DOD

9.6

Liver (other sites), paracaval LN

Fatigue

1

GI pain, diarrhea

1

 

Liver

15.7

PR

DOD

6.1

Paraaortic LN

Nausea

1

GI pain, diarrhea

1

 

Lymph node

15.7

PR

DOD

6.1

Paraaortic LN

Nausea

1

GI pain, diarrhea

1

2

Liver

17.2

SD

DOD

13.1

Liver (other sites)

Nausea

2

Biliary stenosis

3

3

Liver

8.6

PR

DOD

1.6

Liver (other sites)

Fatigue

1

GI pain

2

4

Liver

2.4

SD

DOC

-

-

GI pain

1

-

-

5

Liver

21.8

CR

NED

-

-

Nausea

2

-

-

6

Liver

19.8

PR

DOC

-

-

Nausea

2

Liver failure

5

7

Liver

5.9

SD

DOD

3.8

Mesenteric LN

GI pain

2

GI pain

2

8

Liver

11.3

SD

AWD

1.8

Liver (other sites), lung

Nausea, GI pain

2

GI pain

2

9

Adrenal

11.3

CR

AWD

6.5

Liver

-

-

-

-

10

Liver

3.1

CR

NED

-

-

Nausea

2

-

-

  1. Abbreviations: RECIST Response Evaluation Criteria in Solid Tumors, FFDM Freedom from distant progression, PR Partial response, SD Stable disease, CR Complete response, DOD Dead of disease, DOC Dead of other causes, NED No evidence of disease, AWD Alive with disease, LN Lymph node, GI Gastrointestinal.